Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects strong financial performance, particularly with the YARTEMLEA launch driving significant revenue. Positive feedback from hematological oncologists and the anticipation of YARTEMLEA becoming a standard of care are encouraging. The share repurchase program and upfront cash from Novo Nordisk further bolster financial health. However, the lack of specific patient data and management's avoidance of certain disclosures could raise minor concerns. Overall, the positive aspects, including strong revenue and optimistic guidance, outweigh the negatives, suggesting a positive stock price movement.
Key Financial Performance
YARTEMLEA Gross Revenues $11.1 million in the first quarter of 2026, reflecting strong early demand following its mid-January launch.
YARTEMLEA Net Revenues $9.9 million in the first quarter of 2026, reflecting gross to net adjustments of approximately 11%.
Net Income $56.1 million, or $0.78 per share, in the first quarter of 2026, including a $73.1 million noncash mark-to-market gain on the embedded derivative associated with 2029 convertible notes.
Adjusted Net Loss $17.1 million, or $0.24 per share, excluding the $73.1 million noncash item.
Cash and Investments $135.3 million as of March 31, 2026, after retiring the remaining 2026 convertible notes.
Share Repurchase Approximately 360,000 shares repurchased and retired at an average price of $11.70 per share, totaling $4.2 million in the first quarter of 2026.
Upfront Cash from Novo Nordisk Transaction $240 million received at closing to fund operations, including the YARTEMLEA launch.
Costs and Expenses from Continuing Operations $27.3 million in the first quarter of 2026, a decrease of $1.8 million from the fourth quarter of 2025.
Interest Expense $5.9 million in the first quarter of 2026, with contractual cash interest expense at $1.8 million.
Interest and Other Income $1.5 million in the first quarter of 2026, up from $1.1 million in the fourth quarter of 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval and launch of YARTEMLEA: YARTEMLEA, a MASP-2 inhibitor, was approved for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). It is the first approved treatment for this condition and the first inhibitor of the lectin pathway of complement. Launched in January 2026, it generated $11.1 million in gross revenues and $9.9 million in net revenues in Q1 2026.
Expansion of MASP-2 inhibitor platform: Development of OMS1029 (long-acting MASP-2 antibody) and an oral MASP-2 small molecule program for chronic indications such as renal diseases and neurological disorders is underway.
T-CAT platform and OncotoX-AML: Progress in T-CAT platform for targeting multidrug-resistant organisms and OncotoX-AML for treating acute myeloid leukemia (AML) with promising preclinical results.
YARTEMLEA market penetration: Rapid adoption with 30 unique accounts ordering by March 31, 2026. Significant progress in P&T committee approvals across U.S. transplant centers, with 60% of the top 10 centers approved.
International expansion: Marketing authorization application for YARTEMLEA under review by the European Medicines Agency, with a decision expected mid-2026. Exploring partnerships for commercialization outside the U.S.
Financial performance: Net income of $56.1 million in Q1 2026, including a $73.1 million noncash gain. Adjusted net loss was $17.1 million. Ended the quarter with $135.3 million in cash and investments.
Novo Nordisk transaction: Received $240 million upfront cash from the sale of zaltenibart, with potential for $100 million in near-term milestone payments and a total deal value of up to $2.1 billion.
Strategic focus on YARTEMLEA: Priorities include educating transplant care teams, securing institutional access, ensuring reimbursement, and demonstrating economic value through health economics and outcomes research.
Pipeline diversification: Advancing MASP-2 inhibitors, T-CAT platform, and OncotoX-AML to address unmet medical needs in various therapeutic areas.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Hurdles: The FDA has requested additional nonclinical information before starting the inpatient study for OMS527, which could delay the clinical trial timeline.
Market Access and Adoption: YARTEMLEA is in the early stages of launch, and market access and physician adoption are still developing, which introduces uncertainty in revenue projections.
Reimbursement Challenges: While early reimbursement indicators are positive, the company is still working to ensure consistent, timely reimbursement and streamline ordering processes.
Economic Uncertainties: Fluctuations in stock price significantly impact noncash adjustments related to the embedded derivative tied to the 2029 convertible notes, introducing volatility in reported financial results.
Supply Chain and Operational Risks: The company is building its commercial infrastructure, including marketing and launch activities for YARTEMLEA, which could face operational challenges.
Strategic Execution Risks: The company is expanding its MASP-2 program and exploring new indications and partnerships, which require precise execution to avoid delays or missteps.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
YARTEMLEA Revenue and Cash Flow: YARTEMLEA is expected to drive company-wide positive cash flow within 18 months of its mid-January 2026 launch.
Expansion of YARTEMLEA Indications: The company is assessing opportunities to expand YARTEMLEA's label to other indications involving lectin pathway activation, including acute respiratory distress syndrome (ARDS), sickle cell disease, acute kidney injury, solid organ transplant-related TMA, and delayed graft function.
European Market Authorization for YARTEMLEA: A decision on the marketing authorization application for YARTEMLEA in TA-TMA by the European Medicines Agency is expected mid-2026.
Partnerships for YARTEMLEA Commercialization: The company is evaluating potential partnerships for broad ex-U.S. and regional collaborations to support commercialization outside the U.S.
MASP-2 Inhibitor Platform Development: The company is advancing its Phase II ready long-acting MASP-2 antibody (OMS1029) and oral MASP-2 small molecule program, targeting chronic indications such as membranous nephropathy, other renal diseases, and neurological disorders like Parkinson's and Alzheimer's. The initial Phase II indication for OMS1029 is being finalized.
OMS527 for Cocaine Use Disorder: The company is targeting the initiation of an inpatient clinical trial for OMS527 by the end of 2026, pending FDA approval.
T-CAT Platform Development: The company is focusing on developing its T-CAT platform to target multidrug-resistant organisms (MDROs) and plans to advance this novel class of recombinant antibodies.
OncotoX-AML Development: The company is preparing for a first-in-human trial for OncotoX-AML, targeting late 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: During the first quarter, the company repurchased and retired approximately 360,000 shares of common stock at an average price of $11.70 per share, totaling $4.2 million. The company may continue to repurchase shares from time to time, subject to market conditions and other considerations.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How long does it take for YARTEMLEA to be delivered to hospitals after a clinician requests it?
A:Distributors deliver YARTEMLEA to the sites within about 24 hours of receiving the request.
Q:What is the split between adult and pediatric patients in TA-TMA, and how does this reflect in YARTEMLEA requests?
A:The split between adult and pediatric patients in TA-TMA is roughly 85-15. However, early data shows a greater percentage of pediatric patients requesting YARTEMLEA than the expected 15%.
Q:Are pediatric hematological oncologists requesting YARTEMLEA at a greater rate than expected?
A:Yes, there is a larger percentage of pediatric transplanters requesting YARTEMLEA compared to the overall split in TA-TMA between adults and pediatrics.
Q:How many facilities have started prescribing or requesting YARTEMLEA?
A:By March 31, 30 separate accounts had requested YARTEMLEA. Of the top 10 sites, 6 had ordered, and 24 of the top 80 centers had ordered.
Q:What feedback has been received from hematological oncologists about YARTEMLEA?
A:The feedback has been uniformly positive, with impressive results being observed. The company expects YARTEMLEA to become the standard of care for TA-TMA.
Q:How is the split between inventory, U.S. wholesaler sales, and hospital demand expected to play out over the year?
A:Given the short delivery process of 24 hours, inventory at distributors and centers is relatively small, averaging 1 to 1.5 weeks. The company does not have specific data on the number of patients on the drug due to limited information from centers.
Q:What are the thoughts on AstraZeneca's Ultomiris Phase III study in TMA?
A:AstraZeneca changed its endpoint from response to survival after a 17% response rate in their pediatric open-label trial. The primary endpoint is now event-free survival, with secondary endpoints including duration of response and relapse.
Q:What efforts are being made to recognize TMA earlier, and how might NTAP facilitate earlier intervention?
A:Efforts are focused on increasing awareness within the transplant community about the benefits of earlier intervention. NTAP subsidizes Medicare inpatient payments, which could facilitate earlier treatment.
Q:Can the number of vials dispersed from distributors be disclosed?
A:No, the company is only providing gross and net revenue numbers.
Q:What is the gross-to-net percentage for YARTEMLEA, and how might it change?
A:The gross-to-net percentage for Q1 was 11%, primarily due to chargebacks and fees. It is expected to remain in the teens as 340B participation increases.
Q:What is the status of P&T approvals for YARTEMLEA?
A:P&T approvals are progressing well, with many centers approving access to the drug even without formal P&T approval. The majority of approvals are expected in the next few months.
Q:What impact will the J-code and NTAP have on YARTEMLEA uptake?
A:The J-code, effective July 1, will streamline billing and reimbursement. The NTAP, expected to be finalized in August and effective November 1, will subsidize Medicare inpatient payments, likely driving increased utilization.
Q:Review of Unclear Management Responses
A:The management avoided providing a specific number of patients currently on YARTEMLEA, citing limited information from centers. Additionally, they did not disclose the number of vials dispersed from distributors, only providing gross and net revenue numbers.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CAT
DRI
Interest
MASP
NTAP
Omeros
OncotoX AML
PT committee
TA TMA
YARTEMLEA
adjustment derivative
cash
cell
center
closing
committee approval
derivative note
gain
income
inhibitor
interest
launch
loss
market adjustment
noncash
payment
platform
price share
program
reimbursement
revenue
royalty
stock price
study
transplant
treatment
zaltenibart
OMER Transcript
Omeros Corporation (OMER) Q1 2026 Earnings Call Transcript
Positive5-13
The earnings call reflects strong financial performance, particularly with the YARTEMLEA launch driving significant revenue. Positive feedback from hematological oncologists and the anticipation of YARTEMLEA becoming a standard of care are encouraging. The share repurchase program and upfront cash from Novo Nordisk further bolster financial health. However, the lack of specific patient data and management's avoidance of certain disclosures could raise minor concerns. Overall, the positive aspects, including strong revenue and optimistic guidance, outweigh the negatives, suggesting a positive stock price movement.
Omeros Corporation (OMER) Q4 2025 Earnings Call Transcript
Unknown4-1
With no specific details or updates provided in the earnings call summary or Q&A session, it's challenging to anticipate any significant stock price movement. The lack of information on financial performance, strategic initiatives, and shareholder returns suggests a neutral sentiment, as there are no positive or negative catalysts to influence the stock price within the next two weeks.
Verrica Pharmaceuticals Inc. (VRCA) Q3 2025 Earnings Call Transcript
Positive11-17
The earnings call highlights significant revenue growth, improved margins, and reduced losses, indicating strong financial health. Positive feedback on YCANTH, sales force expansion, and strategic positioning further support a positive sentiment. Despite some uncertainties in the EU filing timeline and specific KPIs, the overall outlook, including optimistic guidance and strategic initiatives, suggests a positive stock price movement. The absence of major negative factors and the potential market expansion for YCANTH contribute to the positive rating.
Omeros Corporation (OMER) Q3 2025 Earnings Call Transcript
Unknown11-17
The earnings call indicates mixed signals: while there are promising developments like the potential approval of narsoplimab and strategic financial moves (e.g., debt repayment), there are also concerns such as increased net loss, cash burn, and uncertainties in clinical trials. The Q&A session did not provide clarity on revenue projections or labeling discussions, adding to the uncertainty. Given the lack of clear positive or negative catalysts, the stock price is likely to remain stable, falling into the neutral category.
OMER Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
